CEACAM5 and B-cell non-Hodgkin lymphoma: Further developments in this field include CD123-CAR Vδ1 T cells against acute myeloid leukemia (AML) (89), carcinoembryonic antigen (CEA)-CAR Vγ9Vδ2 T cells against xenograft mouse model with CEA+ tumor (83), B7H3-CAR Vγ9Vδ2 T cells against glioblastoma (84), CD20-CAR Vγ9Vδ2 T cells with conjugated rituximab against B cell lymphoma (92), and HLA-G and PD-L1 multi-specific CAR Vδ2 T cells with the ability to secrete PD-L1/CD3ε bispecific T cell engagers (BiTEs, which recruit bystander T cells) against solid tumors (93).